Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 NBTXR3 + Radiotherapy ± Cetuximab in Elderly Platinum-ineligible LA HNSCC
2024-513082-39-00Phase 2Completed
- Sponsor
- Nanobiotix
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 15
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing NBTXR3 + radiotherapy ± Erbitux with Radiotherapy ± Erbitux (control) (2 arms). Primary endpoint: Progression-free survival (PFS). Started Nov 2024; status: completed.
02
Drugs
NBTXR3cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513082-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513082-39-00.